| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
a National Cancer Institute, Bethesda, Maryland; b Memorial Sloan-Kettering Cancer Center, New York, New York; c Evanston Northwestern Healthcare, Evanston, Illinois; d Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts; e Stanford University Medical Center, Stanford, California; f Ortho Biotech Products, L.P., Raritan, New Jersey; g Vanderbilt University, Nashville, Tennessee; h University of California San Francisco, San Francisco, California; i The National Coalition for Cancer Survivorship, Silver Spring, Maryland; j Beth Israel Medical Center, New York, New York; k The University of Chicago, Chicago, Illinois
Correspondence: Gregory A. Curt, M.D., National Cancer Institute, 12N214 Room Bldg. 10, Bethesda, Maryland 20892-0001, USA; Telephone: 301-496-4251; Fax: 301-496-9962; e-mail: gc45e{at}nih.gov
Purpose. This survey was designed to confirm the prevalence and duration of fatigue in the cancer population and to assess its physical, mental, social, and economic impacts on the lives of patients and caregivers.
Patients and Methods. A 25-minute telephone interview was completed with 379 cancer patients having a prior history of chemotherapy. Patients were recruited from a sample of 6,125 households in the United States identified as having a member with cancer. The median patient age was 62 years, and 79% of respondents were women. Patients reporting fatigue at least a few times a month were asked a series of questions to better describe their fatigue and its impact on quality of life.
Results. Seventy-six percent of patients experienced fatigue at least a few days each month during their most recent chemotherapy; 30% experienced fatigue on a daily basis. Ninety-one percent of those who experienced fatigue reported that it prevented a "normal" life, and 88% indicated that fatigue caused an alteration in their daily routine. Fatigue made it more difficult to participate in social activities and perform typical cognitive tasks. Of the 177 patients who were employed, 75% changed their employment status as a result of fatigue. Furthermore, 65% of patients indicated that their fatigue resulted in their caregivers taking at least one day (mean, 4.5 days) off work in a typical month. Physicians were the health care professionals most commonly consulted (79%) to discuss fatigue. Bed rest/ relaxation was the most common treatment recommendation (37%); 40% of patients were not offered any recommendations.
Conclusions. Cancer-related fatigue is common among cancer patients who have received chemotherapy and results in substantial adverse physical, psychosocial, and economic consequences for both patients and caregivers. Given the impact of fatigue, treatment options should be routinely considered in the care of patients with cancer.
Related articles in The Oncologist:
This article has been cited by other articles:
 |
|
 |
|
  F. Bozzetti and L. Mariani Defining and Classifying Cancer Cachexia: A Proposal by the SCRINIO Working Group JPEN J Parenter Enteral Nutr, July 1, 2009; 33(4): 361 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Spathis, R Dhillan, D Booden, K Forbes, K Vrotsou, and K Fife Modafinil for the treatment of fatigue in lung cancer: a pilot study Palliative Medicine, June 1, 2009; 23(4): 325 - 331. [Abstract] [PDF]
|
|
|
|
 |
|
 B. D. Thombs, M. Bassel, L. McGuire, M. T. Smith, M. Hudson, and J. A. Haythornthwaite A systematic comparison of fatigue levels in systemic sclerosis with general population, cancer and rheumatic disease samples Rheumatology, October 1, 2008; 47(10): 1559 - 1563. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Dy, K. A. Lorenz, A. Naeim, H. Sanati, A. Walling, and S. M. Asch Evidence-Based Recommendations for Cancer Fatigue, Anorexia, Depression, and Dyspnea J. Clin. Oncol., August 10, 2008; 26(23): 3886 - 3895. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Bower Behavioral Symptoms in Patients With Breast Cancer and Survivors J. Clin. Oncol., February 10, 2008; 26(5): 768 - 777. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Radbruch, F. Strasser, F. Elsner, J. F. Goncalves, J. Loge, S. Kaasa, F. Nauck, P. Stone, and the Research Steering Committee of the European As Fatigue in palliative care patients -- an EAPC approach Palliative Medicine, January 1, 2008; 22(1): 13 - 32. [Abstract] [PDF]
|
|
|
|
 |
|
 H. Sikand, A. Decter, T. Greco, S. H Watson, Y. J. Kang, S. H Mody, C. T. Piech, M. S. Duh, and A. Naeem Cost Analytic Model to Determine the Least Costly Inpatient Erythropoiesis Stimulating Therapy Regimen Ann. Pharmacother., January 1, 2008; 42(1): 16 - 23. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Muller and D. Baribeault Extended-dosage-interval regimens of erythropoietic agents in chemotherapy-induced anemia Am. J. Health Syst. Pharm., December 15, 2007; 64(24): 2547 - 2556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. S. Courneya, R. J. Segal, J. R. Mackey, K. Gelmon, R. D. Reid, C. M. Friedenreich, A. B. Ladha, C. Proulx, J. K.H. Vallance, K. Lane, et al. Effects of Aerobic and Resistance Exercise in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Multicenter Randomized Controlled Trial J. Clin. Oncol., October 1, 2007; 25(28): 4396 - 4404. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Charu, C. P. Belani, A. N. Gill, M. Bhatt, D. Tomita, G. Rossi, and A. Ben-Jacob Efficacy and Safety of Every-2-Week Darbepoetin Alfa in Patients with Anemia of Cancer: A Controlled, Randomized, Open-Label Phase II Trial Oncologist, June 1, 2007; 12(6): 727 - 737. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Boccia, T. Lillie, D. Tomita, and L. Balducci The Effectiveness of Darbepoetin Alfa Administered Every 3 Weeks on Hematologic Outcomes and Quality of Life in Older Patients With Chemotherapy-Induced Anemia Oncologist, May 1, 2007; 12(5): 584 - 593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hofman, J. L. Ryan, C. D. Figueroa-Moseley, P. Jean-Pierre, and G. R. Morrow Cancer-Related Fatigue: The Scale of the Problem Oncologist, May 1, 2007; 12(suppl_1): 4 - 10. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Carroll, S. Kohli, K. M. Mustian, J. A. Roscoe, and G. R. Morrow Pharmacologic Treatment of Cancer-Related Fatigue Oncologist, May 1, 2007; 12(suppl_1): 43 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Mustian, G. R. Morrow, J. K. Carroll, C. D. Figueroa-Moseley, P. Jean-Pierre, and G. C. Williams Integrative Nonpharmacologic Behavioral Interventions for the Management of Cancer-Related Fatigue Oncologist, May 1, 2007; 12(suppl_1): 52 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A Echteld, L. van Zuylen, M. Bannink, E. Witkamp, and C. C. Van der Rijt Changes in and correlates of individual quality of life in advanced cancer patients admitted to an academic unit for palliative care Palliative Medicine, April 1, 2007; 21(3): 199 - 205. [Abstract] [PDF]
|
|
|
|
 |
|
 K. L. Tsang, L. E. Carlson, and K. Olson Pilot Crossover Trial of Reiki Versus Rest for Treating Cancer-Related Fatigue Integr Cancer Ther, March 1, 2007; 6(1): 25 - 35. [Abstract] [PDF]
|
|
|
|
|
|
R. N. Schwartz Anemia in patients with cancer: Incidence, causes, impact, management, and use of treatment guidelines and protocols Am. J. Health Syst. Pharm., February 1, 2007; 64(3_Supplement_2): S5 - S13. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Kim Cost of Cancer Care: The Patient Perspective J. Clin. Oncol., January 10, 2007; 25(2): 228 - 232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Hartvig, J. Aulin, S. Wallenberg, and G. Wagenius Physical exercise for cytotoxic drug-induced fatigue Journal of Oncology Pharmacy Practice, December 1, 2006; 12(4): 183 - 191. [Abstract] [PDF]
|
|
|
|
|
|
J. H. Savonije, C. J. van Groeningen, L. W. Wormhoudt, and G. Giaccone Early Intervention with Epoetin Alfa During Platinum-Based Chemotherapy: An Analysis of Quality-of-Life Results of a Multicenter, Randomized, Controlled Trial Compared with Population Normative Data. Oncologist, February 1, 2006; 11(2): 197 - 205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Poirier Policy Implications of the Relationship of Sick Leave Benefits, Individual Characteristics, and Fatigue to Employment During Radiation Therapy for Cancer Policy Politics Nursing Practice, November 1, 2005; 6(4): 305 - 318. [Abstract] [PDF]
|
|
|
|
|
|
P. Barrett-Lee, C. Bokemeyer, P. Gascon, J.W.R. Nortier, M. Schneider, D. Schrijvers, S. Van Belle, and for the Ecas Advisory Board and Participating Cent Management of Cancer-Related Anemia in Patients with Breast or Gynecologic Cancer: New Insights Based on Results from the European Cancer Anemia Survey Oncologist, October 1, 2005; 10(9): 743 - 757. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Waltzman, C. Croot, G. R. Justice, M. R. Fesen, V. Charu, and D. Williams Randomized Comparison of Epoetin Alfa (40,000 U Weekly) and Darbepoetin Alfa (200 {micro}g Every 2 Weeks) in Anemic Patients with Cancer Receiving Chemotherapy Oncologist, September 1, 2005; 10(8): 642 - 650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Meeske, S. E. Siegel, D. R. Globe, W. J. Mack, and L. Bernstein Prevalence and Correlates of Fatigue in Long-Term Survivors of Childhood Leukemia J. Clin. Oncol., August 20, 2005; 23(24): 5501 - 5510. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Leonard, M. Untch, and F. Von Koch Management of anaemia in patients with breast cancer: role of epoetin Ann. Onc., May 1, 2005; 16(5): 817 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Herrington, S. L. Davidson, D. K. Tomita, L. Green, R. E. Smith, and R. V. Boccia Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia Am. J. Health Syst. Pharm., January 1, 2005; 62(1): 54 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Couture, A.R. Turner, B. Melosky, L. Xiu, R.K. Plante, C.Y. Lau, and I. Quirt Prior Red Blood Cell Transfusions in Cancer Patients Increase the Risk of Subsequent Transfusions With or Without Recombinant Human Erythropoietin Management Oncologist, January 1, 2005; 10(1): 63 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Walke, W. T. Gallo, M. E. Tinetti, and T. R. Fried The Burden of Symptoms Among Community-Dwelling Older Persons With Advanced Chronic Disease Arch Intern Med, November 22, 2004; 164(21): 2321 - 2324. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Blackwell, P. Gascon, G. Sigounas, and L. Jolliffe rHuEPO and Improved Treatment Outcomes: Potential Modes of Action Oncologist, November 1, 2004; 9(suppl_5): 41 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Hudis, S. Van Belle, J. Chang, and K. Muenstedt rHuEPO and Treatment Outcomes: the Clinical Experience Oncologist, November 1, 2004; 9(suppl_5): 55 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Watson and V. Mock Exercise as an Intervention for Cancer-Related Fatigue Physical Therapy, August 1, 2004; 84(8): 736 - 743. [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Lawrence, B. Kupelnick, K. Miller, D. Devine, and J. Lau Evidence Report on the Occurrence, Assessment, and Treatment of Fatigue in Cancer Patients J Natl Cancer Inst Monographs, July 1, 2004; 2004(32): 40 - 50. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Nail My Get Up and Go Got Up and Went: Fatigue in People With Cancer J Natl Cancer Inst Monographs, July 1, 2004; 2004(32): 72 - 75. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Mock Evidence-Based Treatment for Cancer-Related Fatigue J Natl Cancer Inst Monographs, July 1, 2004; 2004(32): 112 - 118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Cella, J. Kallich, A. McDermott, and X. Xu The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials Ann. Onc., June 1, 2004; 15(6): 979 - 986. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Iop, A. M. Manfredi, and S. Bonura Fatigue in cancer patients receiving chemotherapy: an analysis of published studies Ann. Onc., May 1, 2004; 15(5): 712 - 720. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Vickers, D. J. Straus, B. Fearon, and B. R. Cassileth Acupuncture for Postchemotherapy Fatigue: A Phase II Study J. Clin. Oncol., May 1, 2004; 22(9): 1731 - 1735. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Henry, P. Bowers, M. T. Romano, and R. Provenzano Epoetin Alfa: Clinical Evolution of a Pleiotropic Cytokine Arch Intern Med, February 9, 2004; 164(3): 262 - 276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Patton, M. Kuzur, W. Liggett, F. Miranda, H. Varsos, and L. Porter Epoetin Alfa 60,000 U Once Weekly Followed by 120,000 U Every 3 Weeks Increases and Maintains Hemoglobin Levels in Anemic Cancer Patients Undergoing Chemotherapy Oncologist, February 1, 2004; 9(1): 90 - 96. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Henry The Evolving Role of Epoetin Alfa in Cancer Therapy Oncologist, February 1, 2004; 9(1): 97 - 107. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Knobel, J. H. Loge, E. Brenne, P. Fayers, M. J. Hjermstad, and S. Kaasa The validity of EORTC QLQ-C30 fatigue scale in advanced cancer patients and cancer survivors Palliative Medicine, December 1, 2003; 17(8): 664 - 672. [Abstract] [PDF]
|
|
|
|
|
|
B. Coiffier Advocating recombinant human erythropoietin as standard practice in Europe for treatment of cancer-related anaemia Ann. Onc., May 1, 2003; 14(5): 804 - 804. [Full Text] [PDF]
|
|
|
|
|
|
K. S. Courneya, J. R. Mackey, G. J. Bell, L. W. Jones, C. J. Field, and A. S. Fairey Randomized Controlled Trial of Exercise Training in Postmenopausal Breast Cancer Survivors: Cardiopulmonary and Quality of Life Outcomes J. Clin. Oncol., May 1, 2003; 21(9): 1660 - 1668. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Cella, D. Dobrez, and J. Glaspy Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes Ann. Onc., April 1, 2003; 14(4): 511 - 519. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Dicato Anemia in Cancer: Some Pathophysiological Aspects Oncologist, February 1, 2003; 8(90001): 19 - 21. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Curt and P. G. Johnston Cancer Fatigue: The Way Forward Oncologist, February 1, 2003; 8(90001): 27 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Cella, M. J. Zagari, C. Vandoros, D. D. Gagnon, H.-J. Hurtz, and J. W.R. Nortier Epoetin Alfa Treatment Results in Clinically Significant Improvements in Quality of Life in Anemic Cancer Patients When Referenced to the General Population J. Clin. Oncol., January 15, 2003; 21(2): 366 - 373. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. Detmar, M. J. Muller, J. H. Schornagel, L. D. V. Wever, and N. K. Aaronson Health-Related Quality-of-Life Assessments and Patient-Physician Communication: A Randomized Controlled Trial JAMA, December 18, 2002; 288(23): 3027 - 3034. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Gordon Managing Anemia in the Cancer Patient: Old Problems, Future Solutions Oncologist, August 1, 2002; 7(4): 331 - 341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E A Thompson and D Reilly The homeopathic approach to symptom control in the cancer patient: a prospective observational study Palliative Medicine, April 1, 2002; 16(3): 227 - 233. [Abstract] [PDF]
|
|
|
|
|
|
J. Glaspy, L. Degos, M. Dicato, and G. D. Demetri Comparable Efficacy of Epoetin Alfa for Anemic Cancer Patients Receiving Platinum- and Nonplatinum-Based Chemotherapy: A Retrospective Subanalysis of Two Large, Community-Based Trials Oncologist, April 1, 2002; 7(2): 126 - 135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Itri Cancer-related anaemia requires higher doses of epoetin alfa than chronic renal failure replacement therapy Nephrol. Dial. Transplant., December 1, 2001; 16(12): 2289 - 2293. [Full Text] [PDF]
|
|
|
|
|
|
H. Knobel, J. H. Loge, M. B. Lund, K./o. Forfang, O. Nome, and S. Kaasa Late Medical Complications and Fatigue in Hodgkin's Disease Survivors J. Clin. Oncol., July 1, 2001; 19(13): 3226 - 3233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A Curt Fatigue in cancer BMJ, June 30, 2001; 322(7302): 1560 - 1560. [Full Text]
|
|
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |
